OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Officer received an award of 36K ALKS derivative securities | OQRO

Home
Insider trades
Alkermes plc
Officer received an award of 36K ALKS derivative securities

Insider trades

Insider trade

Officer received an award of 36K ALKS derivative securities

Traded Mar 2, 2026 · Filed Mar 5, 2026

ALKAlkermes plcALKS

36K
Derivative units

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Mar 2, 2026
Reporting period: Not applicable
Filed with the SEC: Mar 5, 2026

OfficerGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001520262-26-000057
Filed / recorded

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Mar 5, 2026, 1:15 AM UTC

Added to OQRO

Oct 6, 2026, 9:54 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

Alkermes plc.

Issuer CIK

1520262

Ticker

ALKS

Reporting person

David Joseph Gaffin

Relationship

Officer

Officer title

EVP, CLO, Alkermes, Inc.

Security

Restricted Stock Unit Award

Table

Derivative (Table II)

Transaction date

Mar 2, 2026

Transaction code

Shares / units

36,364

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

36,364

Ownership form

Direct

Amendment

Footnotes from the filing

Each restricted stock unit represents a contingent right to receive one ordinary share.
Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 3/2/2027.

Around the same time

Craig C. HopkinsonEVP R&D, Chief Medical Officer

Filed 6mo ago

5,000Shares · @ $19.34

Traded Apr 1 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record

Craig C. Hopkinson (EVP R&D, Chief Medical Officer) sold ~$320K of Alkermes plc

Scheduled in advanceFiled 6mo ago

Craig C. HopkinsonEVP R&D, Chief Medical Officer

Filed 6mo ago

5,000Derivative units

Traded Apr 1 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record